To amend title XI of the Social Security Act to alter when biosimilar biological products are eligible for price negotiations under the Medicare program.

HR 10628 · In committee · last action September 28, 2026

Plain-language summary not yet available.

Sponsor

No votes recorded against this bill yet — vote coverage is a work in progress.